Wine producer makes it easy for patients to pay for pain medication
Vinegar cleaning solutions can help patients pay for prescription pain medication, the company behind the product says.
The product is available as a generic version in Britain, New Zealand, Australia, the US and Canada.
The company, which makes a range of products, says the treatment helps patients “feel better, less fatigued, and reduce symptoms in the long term”.
It says patients who have been using the product “may feel like they have never been able to afford medication”.
The company is calling the product an “invention”.
The UK-based company, known as Verve, says it will be able to offer the drug to the public in the coming weeks.
The drug has been shown to reduce pain in patients with a wide range of conditions including Crohn’s disease, multiple sclerosis, fibromyalgia and arthritis.
Verve says it aims to bring the drug’s price down to $10 per tablet.
“It will be available for patients in the UK, Australia and New Zealand who require prescription pain medicine, and for those who have difficulty paying for it,” it said.
“The product also provides patients with more choice of pain medicines and the ability to get them at a lower cost.”
As a leading global supplier of prescription pain medicines, Verve has long been a leader in the field of generic pain medicines.
“The company says it hopes to have its drug available to patients by Christmas.
The British drug maker says its patented compound, called stomatostatin, is also used to treat hypertension and is “complementary” to existing medications.
It said the drug is currently being tested in trials in a number of countries, including India, the Netherlands, France and the US.
Verve said it had a long history of developing the compound and it was “proud” to be able “to take the next step” with the drug. “
The ability to treat chronic pain in a novel way that does not require medication is a revolutionary innovation, and it’s the type of innovation that is driving the demand for more generic pain drugs, the demand that will drive the growth of this product,” the company said.
Verve said it had a long history of developing the compound and it was “proud” to be able “to take the next step” with the drug.
The company has said its new compound is similar to a drug currently in development, called rosiglitazone, which has been used in people with rheumatoid arthritis and rheumatic fever.
This drug is also being tested for treating chronic pain.
The UK company is also looking to raise $150 million from the US venture capital firm Andreessen Horowitz to develop the product.
A spokesman for Verve said the company was exploring “market opportunities in Australia, Canada and the United States”.
The spokesman said the business would also explore “other potential markets, including emerging markets”.
“The new compound will enable Verve to reach a wider range of patients, including those in remote and remote communities who may not otherwise be able or willing to pay the current cost of treatment,” the spokesman said.
He added that the company had been “very proud” of the product and would continue to develop it.
Earlier this year, Vervo announced plans to enter Australia with a “major” manufacturing facility in the Adelaide Hills.
Its plant will be the biggest in the country.
According to the company’s website, it has manufacturing capacity in England, Australia’s South West, New South Wales, Victoria, South Africa, Queensland and Western Australia.
Read more:Australian government backs Vinegar Cleaning Solution to lower prescription drug prices